GW caps off top year with start of Phase III with Sativex in cancer pain
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals, the cannabinoid-focused company, has capped off a strong year with an impressive set of results and the initiation of a Phase III programme in cancer pain for its lead product Sativex.